Summary:
This study will be an open-label, 12 month study to assess PRN usage of STS101 (DHE nasal powder) for migraine treatment.Study participants will be able to use up to 2 doses of STS101 to treat a single migraine attack within 24 hours and can use up to 12 doses of STS101 per month for 12 months.
Qualified Participants Must:
• Between 18-65 years of age
•
Have had migraine onset before 50 years of age
•
History of 4-12 migraine attacks per month on average
•
Have to be tobacco free for at least 1 year prior to screening
Qualified Participants May Receive:
- Compensation for time and travel expenses
- Laboratory testing such as blood work and an EKG
- Physical performed by a board certified physician